Podcasts

E-Books

Videos

Articles

Clinical

Skylar Jeremias is the Managing Editor for The Center for Biosimilars and The American Journal of Managed Care (AJMC).

Minute differences between biosimilars and reference products are not considered “clinically meaningful,” but these differences are exploitable when it comes to addressing allergies related to originator products.

Providers Exploit Minor Differences Between Innovator Drugs and Biosimilars

Bincy P. Abraham, MD, MS, AGAF, FACG, is a professor of Clinical Medicine at Houston Methodist Academic Institute. She is also the distinguished professor and director of the Fondren Inflammatory Bowel Disease Program at the Underwood Center for Digestive Disorders and director of Gastroenterology Fellowship Program at Houston Methodist Hospital.

Bincy P. Abraham, MD, explains that even when payers allow coverage for biosimilars, providers may still be hesitant to use them. 

Opinion: Embrace the Era of Next-Generation Biologics

Tony Hagen is senior managing editor for The Center for Biosimilars

The rheumatology and gastroenterology biosimilar candidate would enter the lucrative market established by Humira.

Alvotech Files for US and EU Approval of Adalimumab Biosimilar

Investigators said their study is valuable because biosimilar switching is likely to increase for economic reasons. 

High Patient Retention Observed for Multiple Etanercept Switches

The International Generic and Biosimilar Medicines Association (IGBA) hopes to build momentum for the use of biosimilars. 

IGBA Launches Global Biosimilars Week

Investigators looked at adherence in patients who switched from reference infliximab during treatment for rheumatologic and gastrointestinal treatment. 

High Adherence Noted Among Infliximab Biosimilar Users

US Rheumatologists Understand and Accept Biosimilars, but Some Hesitation Remains

The company is targeting the lucrative osteoporosis market dominated by Prolia, an Amgen product.

Samsung Launches Clinical Study of Denosumab Candidate

A multibiomarker disease activity score looks at serum protein activity for a more sensitive evaluation of biosimilarity, investigators said at the American College of Rheumatology Convergence 2020 meeting.

Multibiomarker Test Reads Out Positive in 2 Pfizer-Sponsored Studies

Poster presentations at the American College of Rheumatology (ACR) Convergence 2020 meeting shed light on performance of adalimumab versions. 

Rheumatology